Description:

The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR). NCT00516321 https://clinicaltrials.gov/ct2/show/NCT00516321 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin

Link:

https://clinicaltrials.gov/ct2/show/NCT00516321

Keywords:
Versions (1) ▾
  1. 5/31/17
Uploaded on:

May 31, 2017

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Lab panels NCT00516321

Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Lab panels NCT00516321

Chemistry
[iU]/L
[iU]/L
[iU]/L
mmol/L
mmol/L
mmol/L
mmol/L
umol/L
umol/L
umol/L
umol/L
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
g/L
ng/mL
Haematology
10*6/uL
g/L
10*3/uL
10*3/uL
10*3/uL
10*3/uL
10*3/uL
10*3/uL
10*3/uL
fL
ng/L
Liver Chemistry Assessments
g/L
Renal Laboratory Parameters
umol/L
mL/min
Urinalysis Dipstick
umol/L
g/L
Ery/uL
mmol/L
mmol/L
Other Laboratory Screenings
[iU]/L
[iU]/L
[iU]/L